Business Milestones
2025.06.16
TAHO Pharmaceuticals Secures Two Taiwan Patents for TAH3311 Apixaban Anticoagulant Oral Dissolving Film
Taipei — June 16, 2025 – TAHO Pharmaceuticals Ltd. announced that the Taiwanese Patent Office has granted two important patents related to its innovative Apixaban oral dissolving film product, TAH3311. The patents cover "Apixaban Film Product and Uses Thereof" and "Use of Apixaban Film Product in Treating Thrombosis," significantly enhancing TAHO’s competitive position in the thrombosis treatment market in Taiwan and the broader Asia-Pacific region.
Patients with swallowing difficulties, such as stroke survivors, the elderly, or young children, often face challenges with traditional anticoagulant tablets. These tablets typically require crushing into powder, mixing with water, and careful administration, which can lead to dosage errors, mess, and added stress for both patients and caregivers. This cumbersome process can hinder medication adherence and increase caregiver workload.
TAH3311, powered by TAHO’s proprietary Transepithelial Delivery System (TDS), offers a solution through a rapidly dissolving oral film that absorbs quickly in the mouth without water. This innovative delivery method eliminates the need for crushing or mixing, ensuring accurate dosing, simplifying administration, and enhancing medication adherence while significantly reducing the burden on caregivers.
About TAH3311
TAH3311, the world’s first Apixaban oral dissolving film (ODF), is a groundbreaking product developed by TAHO Pharmaceuticals Ltd. Utilizing TAHO’s proprietary Transepithelial Delivery System (TDS), TAH3311 dissolves instantly in the mouth without the need for water, providing a convenient, user- friendly experience for stroke survivors, the elderly, and others who face challenges swallowing pills. Proven bioequivalent to Eliquis ® in pivotal clinical studies, TAH3311 is prepared for regulatory submissions to the FDA and EMA. With millions of patients requiring blood thinners annually—and over $26 billion spent in the U.S. alone (Source: IQVIA 2024)—TAH3311 aims to deliver simpler, more compassionate care worldwide.
Patients with swallowing difficulties, such as stroke survivors, the elderly, or young children, often face challenges with traditional anticoagulant tablets. These tablets typically require crushing into powder, mixing with water, and careful administration, which can lead to dosage errors, mess, and added stress for both patients and caregivers. This cumbersome process can hinder medication adherence and increase caregiver workload.
TAH3311, powered by TAHO’s proprietary Transepithelial Delivery System (TDS), offers a solution through a rapidly dissolving oral film that absorbs quickly in the mouth without water. This innovative delivery method eliminates the need for crushing or mixing, ensuring accurate dosing, simplifying administration, and enhancing medication adherence while significantly reducing the burden on caregivers.
About TAH3311
TAH3311, the world’s first Apixaban oral dissolving film (ODF), is a groundbreaking product developed by TAHO Pharmaceuticals Ltd. Utilizing TAHO’s proprietary Transepithelial Delivery System (TDS), TAH3311 dissolves instantly in the mouth without the need for water, providing a convenient, user- friendly experience for stroke survivors, the elderly, and others who face challenges swallowing pills. Proven bioequivalent to Eliquis ® in pivotal clinical studies, TAH3311 is prepared for regulatory submissions to the FDA and EMA. With millions of patients requiring blood thinners annually—and over $26 billion spent in the U.S. alone (Source: IQVIA 2024)—TAH3311 aims to deliver simpler, more compassionate care worldwide.